Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 6/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 2/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27644853 | 0.84 | HTR6 (0.45) | HTR6PDK4CCNT1CDK9 | |
| SCHEMBL21714219 | 0.81 | CCNT1 (0.51) | HTR6CCNT1CDK9GPR119SCN9A | |
| SCHEMBL20919965 | 0.80 | HTR6 (0.52) | HTR6GPR119 | |
| SCHEMBL19297244 | 0.78 | PDK4 (0.58) | HTR6PDK4GRM5GRM1CNR1 | |
| SCHEMBL4318186 | 0.77 | HTR6 (0.53) | HTR6PDK4GRM5GRM1TNK2 | |
| SCHEMBL16039939 | 0.77 | HTR6 (0.51) | HTR6PDK4GRM5GRM1CCNT1 | |
| SCHEMBL38663138 | 0.76 | PDK4 (0.55) | HTR6PDK4GRM5GRM1CNR1 | |
| SCHEMBL16040944 | 0.75 | HTR6 (0.49) | HTR6PDK4GRM5GRM1TNK2 | |
| SCHEMBL4879856 | 0.75 | HTR6 (0.56) | HTR6PDK4GRM5GRM1SCN9A | |
| SCHEMBL15622091 | 0.74 | HTR6 (0.43) | HTR6PDK4GRM5GRM1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR6 3427/4885PDK4 813/4885GRM5 4359/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR6 3427/4885PDK4 813/4885GRM5 4359/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR6 3427/4885PDK4 813/4885GRM5 4359/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | HTR6 3533/4885PDK4 559/4885GRM5 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.